APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Solid Tumors · Advanced Cancer · Renal Cancer · Gastric Cancer · Gastroesophageal Junction Adenocarcinoma · NSCLC · Lung Cancer · Brain Tumor · Glioblastoma Multiforme · EGFR Gene Mutation · MET Amplification · HGF · Thyroid Cancer · Pancreatic Cancer · Colon Cancer · MET Alteration · MET Fusion · Exon 14 Skipping
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 497 (planned)
- Started
- Sep 27, 2017
- Main results expected
- Mar 30, 2026
- Fully finished
- Nov 30, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Objective response rate (ORR = CR + PR) per IRC committee (BIRC) based on RECIST v1.1 (or relevant criteria per tumor type)
Measured over: From time of informed consent signature through completion of treatment (1 cycle = 28 days) or progression
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT03175224 · record last updated 2025-06-27 · checked 2026-11-09 15:36 UTC